A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis
| Autor: | Gheorghe, Liana, Iacob, Speranta, Simionov, Iulia, Caruntu, Florin, Motoc, Adriana, Arama, Victoria, Liliana Preotescu, Stefan, Ion, Goldis, Adrian, Brisc, Cristian, Rugina, Sorin, Rednic, Nicolae |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Liver Cirrhosis Male Adolescent Genotype Proline Gastroenterology Interferon-alpha Hepacivirus Hepatitis C Chronic Interferon alpha-2 Middle Aged Viral Load Prognosis Antiviral Agents Recombinant Proteins Young Adult Treatment Outcome Ribavirin Humans RNA Viral Drug Therapy Combination Female Prospective Studies Aged |
| Zdroj: | Scopus-Elsevier Web of Science |
| ISSN: | 1842-1121 |
| Popis: | Background: A number of high quality randomized clinical trials examining the efficacy and safety of triple therapy in genotype-1 HCV-infected patients have been published. However, these trials included a small number of patients with advanced fibrosis, and selected a population different from that in real-world settings.Aim: To determine the efficacy of boceprevir, pegInterferon and ribavirin regimen in genotype-1 treatment-experienced HCV-infected patients with cirrhosis and bridging fibrosis in real-life setting.Method: 167 treatment-experienced patients (85.6% relapsers) out of which 33.5% had cirrhosis, with a mean age of 52.6 years, registered in the Romanian Name Patient Program Database were included into the study.Results: 16.7% of patients had a viral load >100 IU/mL. Undetectable HCV RNA was encountered in 77.3% of patients at week 12. Multiple logistic regression analysis revealed the following independent predictors, measured at week 8, for an HCV RNA ≥100 IU/mL at week 12 of triple therapy: alanine aminotransferase values (p=0.01), hemoglobin level (p=0.04) and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|